Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study-Reference-Cited by-同舟云学术

Single-agent metronomic versus weekly oral vinorelbine as first-line chemotherapy in patients with HR-positive/HER2-negative advanced breast cancer: The randomized Tempo Breast study

Published:2024-04 Issue: Volume:74 Page:103681
ISSN:0960-9776
Container-title:The Breast
language:en
Short-container-title:The Breast

Author:

Freyer Gilles,Martinez-Jañez Noelia,Kukielka-Budny Bożena,Ulanska Malgorzata,Bourgeois Hugues,Muñoz Montserrat,Morales Serafin,Calero Juan Bayo,Cortesi Laura^ORCID,Pintér Tamás,Palácová Markéta,Cherciu Nelli,Petru Edgar,Ettl Johannes,de Almeida Cécilia,Villanova Gustavo,Raymond Romain,Minh Christine Ta Thanh,Rodrigues Ana,Cazzaniga Marina E.

Publisher

Elsevier BV

Reference26 articles.

1. 5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5);Cardoso;Ann Oncol,2020

2. A multicenter randomized phase II study of oral vs. intravenous vinorelbine in advanced non-small-cell lung cancer patients;Jassem;Ann Oncol,2001

3. Phase II study of oral vinorelbine in first-line advanced breast cancer chemotherapy;Freyer;J Clin Oncol,2003

4. Randomized phase II study evaluating weekly oral vinorelbine versus weekly paclitaxel in estrogen receptor-positive, HER2-negative patients with advanced breast cancer (NorBreast-231 trial);Aapro;Breast,2019

5. ESMO clinical practice guideline for the diagnosis, staging and treatment of patients with metastatic breast cancer;Gennari;Ann Oncol,2021

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Metronomic chemotherapy using capecitabine and cyclophosphamide in metastatic breast cancer – efficacy, tolerability and quality of life results from the phase II METRO trial;The Breast;2024-12